Table 3.
The outcomes of death receptor studies are summarized based on high expression of the markers in question. Oral Cavity (OC), Oropharynx (OP), Hypopharynx (HP), Larynx (L), Lip (Lip), Tongue (T). Overall survival (OS), Disease-free survival (DFS), Progression-free survival (PFS), Distant metastasis-free survival (DMFS), Disease-specific survival (DSS), Local recurrence (LR), Local-regional control (LRC).
| Marker (High expression) | Study | Sample Size | Subsite | Outcome |
|---|---|---|---|---|
| Fas and Fas-L | Fuijeda 2000 | 58 | OC, OP | No correlation with T stage, N stage, clinical stage, LR, OS, DFS |
| Guler 2005 | 26 | OC, OP | High clinical stage | |
| Tsuzuki 2005 | 58 | OP | No correlation with OS | |
| De Carvalho-Neto 2013 | 60 | OC | Fas: Negative lymph nodes, better DSS Fas- L: Worse DFS |
|
| Fas | Bayazit 2000 | 30 | L | No correlation with T stage, N stage, Tumor grade, Tumor site |
| Muraki 2000 | 46 | OC | Better OS, Absence of LR, lower clinical stage. | |
| Jackel 2001 | 88 | L | No correlation with OS, DSS or clinicopathologic parameters | |
| Asensio 2007 | 45 | L | Better survival | |
| Fas-L | Reichert 2002 | 28 | OC | No correlation with T -or N stage |
| Das 2011 | 41 | OC | High clinical stage, higher T and N stage (not statistically significant) | |
| Fang 2013 | 38 | OC | Lymph node metastasis | |
| Peterle 2015 | 64 | OC | Fas-L expression in lymphoid cells correlated with lymph node metastasis, low DFS and low DSS | |
| FADD | Prapinjumrune 2009 | 60 | T | Cervical lymph node metastasis, Worse DSS |
| Schrijvers 2011 | 92 | L | Trend toward better LRC, No correlation with OS or clinicopathologic parameters | |
| Rasamny 2012 | 222 | OP, OC, HP, NP | Worse OS, DSS and DFS | |
| Pattje 2012 | 177 | OP, HP, L, OC | Lymph node metastasis, Shorter DMFS | |
| Fan 2013 | 200 | OP, OC, L | Worse OS and DFS | |
| Chien 2016 | 339 | OP, HP, OC | Lymph node metastasis, Younger age, Higher tumor grade, Worse DFS and OS | |
| Wachters 2017 | 60 | L | No correlation with survival or clinicopathologic parameters | |
| Noorlag 2017 | 158 | OC | Lymph node metastasis | |
| TRAIL | Vigneswaran 2007 | 45 | OC | High TRAIL-R DR5: higher T stage |
| Carcini 2010 | 134 | OC | Worse OS | |
| Erkul 2016 | 20 | L | High TRAIL-R DR5: higher clinical stage | |
| GrB | Costa 2010 | 55 | OC | Better survival, Lower T stages |
| FAP-1 | Nariai 2011 | 50 | OC | Worse OS |